CHMP rejects AB Science’s ALS drug
AB Science’s share price has taken a hit after European Medicine Agency’s advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
Read More
Tag: masitinib
Experimental ALS drug wins EU orphan status
European regulators have assigned orphan drug status to an experimental therapy for Amyotrophic Lateral Sclerosis called masitinib, indicating that it has the potential to offer a significant benefit over existing treatment options.
Read More
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
